BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1050 related articles for article (PubMed ID: 31534499)

  • 1. The miR-26a/AP-2α/Nanog signaling axis mediates stem cell self-renewal and temozolomide resistance in glioma.
    Huang W; Zhong Z; Luo C; Xiao Y; Li L; Zhang X; Yang L; Xiao K; Ning Y; Chen L; Liu Q; Hu X; Zhang J; Ding X; Xiang S
    Theranostics; 2019; 9(19):5497-5516. PubMed ID: 31534499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Warburg effect-promoted exosomal circ_0072083 releasing up-regulates NANGO expression through multiple pathways and enhances temozolomide resistance in glioma.
    Ding C; Yi X; Chen X; Wu Z; You H; Chen X; Zhang G; Sun Y; Bu X; Wu X; Lin Z; Gu J; Lin Y; Kang D
    J Exp Clin Cancer Res; 2021 May; 40(1):164. PubMed ID: 33975615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-29b promotes cell sensitivity to Temozolomide by targeting STAT3 in glioma.
    Xu JX; Yang Y; Zhang X; Luan XP
    Eur Rev Med Pharmacol Sci; 2020 Feb; 24(4):1922-1931. PubMed ID: 32141561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-30a suppresses self-renewal and tumorigenicity of glioma stem cells by blocking the NT5E-dependent Akt signaling pathway.
    Peng L; Ming Y; Zhang L; Zhou J; Xiang W; Zeng S; He H; Chen L
    FASEB J; 2020 Apr; 34(4):5128-5143. PubMed ID: 32067282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-181b-5p modulates chemosensitivity of glioma cells to temozolomide by targeting Bcl-2.
    Zhang X; Yu J; Zhao C; Ren H; Yuan Z; Zhang B; Zhuang J; Wang J; Feng B
    Biomed Pharmacother; 2019 Jan; 109():2192-2202. PubMed ID: 30551476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MSC-AS1 knockdown inhibits cell growth and temozolomide resistance by regulating miR-373-3p/CPEB4 axis in glioma through PI3K/Akt pathway.
    Li C; Feng S; Chen L
    Mol Cell Biochem; 2021 Feb; 476(2):699-713. PubMed ID: 33106913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circ-VPS18 Knockdown Enhances TMZ Sensitivity and Inhibits Glioma Progression by MiR-370/RUNX1 Axis.
    Li W; Ma Q; Liu Q; Yan P; Wang X; Jia X
    J Mol Neurosci; 2021 Jun; 71(6):1234-1244. PubMed ID: 33188501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NCK1-AS1 Increases Drug Resistance of Glioma Cells to Temozolomide by Modulating miR-137/
    Chen M; Cheng Y; Yuan Z; Wang F; Yang L; Zhao H
    Cancer Biother Radiopharm; 2020 Mar; 35(2):101-108. PubMed ID: 31750728
    [No Abstract]   [Full Text] [Related]  

  • 9. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
    Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
    Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms for hypoxia
    Zhao H; Meng L; Liao X; Liu Y; Mo X; Gong M; Liao Y
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Jul; 47(7):829-838. PubMed ID: 36039578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia-mediated mitochondria apoptosis inhibition induces temozolomide treatment resistance through miR-26a/Bad/Bax axis.
    Ge X; Pan MH; Wang L; Li W; Jiang C; He J; Abouzid K; Liu LZ; Shi Z; Jiang BH
    Cell Death Dis; 2018 Nov; 9(11):1128. PubMed ID: 30425242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resveratrol restores sensitivity of glioma cells to temozolamide through inhibiting the activation of Wnt signaling pathway.
    Yang HC; Wang JY; Bu XY; Yang B; Wang BQ; Hu S; Yan ZY; Gao YS; Han SY; Qu MQ
    J Cell Physiol; 2019 May; 234(5):6783-6800. PubMed ID: 30317578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosomal circ-HIPK3 Facilitates Tumor Progression and Temozolomide Resistance by Regulating miR-421/
    Han C; Wang S; Wang H; Zhang J
    Cancer Biother Radiopharm; 2021 Sep; 36(7):537-548. PubMed ID: 32644821
    [No Abstract]   [Full Text] [Related]  

  • 14. miR-519a enhances chemosensitivity and promotes autophagy in glioblastoma by targeting STAT3/Bcl2 signaling pathway.
    Li H; Chen L; Li JJ; Zhou Q; Huang A; Liu WW; Wang K; Gao L; Qi ST; Lu YT
    J Hematol Oncol; 2018 May; 11(1):70. PubMed ID: 29843746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
    Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
    Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT.
    Zhao C; Guo R; Guan F; Ma S; Li M; Wu J; Liu X; Li H; Yang B
    Sci Rep; 2020 Jun; 10(1):9471. PubMed ID: 32528036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.
    Wei J; Qi X; Zhan Q; Zhou D; Yan Q; Wang Y; Mo L; Wan Y; Xie D; Xie J; Yang S
    Biomed Pharmacother; 2015 Apr; 71():112-8. PubMed ID: 25960225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
    Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
    J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circ_0005198 enhances temozolomide resistance of glioma cells through miR-198/TRIM14 axis.
    Deng Y; Zhu H; Xiao L; Liu C; Meng X
    Aging (Albany NY); 2020 Dec; 13(2):2198-2211. PubMed ID: 33316781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knockdown of circHIPK3 Facilitates Temozolomide Sensitivity in Glioma by Regulating Cellular Behaviors Through miR-524-5p/KIF2A-Mediated PI3K/AKT Pathway.
    Yin H; Cui X
    Cancer Biother Radiopharm; 2021 Sep; 36(7):556-567. PubMed ID: 32833501
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 53.